From numerical amplification to functional metamorphosis: the MDSC-driven therapeutic resistance in tumor.
1/5 보강
Myeloid-derived suppressor cells (MDSCs) are a population with immunosuppressive characteristics in the tumor microenvironment, which are linked to poor prognosis and therapeutic resistance across can
APA
Li R, Zhao A, et al. (2026). From numerical amplification to functional metamorphosis: the MDSC-driven therapeutic resistance in tumor.. International journal of surgery (London, England), 112(2), 4861-4879. https://doi.org/10.1097/JS9.0000000000003940
MLA
Li R, et al.. "From numerical amplification to functional metamorphosis: the MDSC-driven therapeutic resistance in tumor.." International journal of surgery (London, England), vol. 112, no. 2, 2026, pp. 4861-4879.
PMID
41222910
Abstract
Myeloid-derived suppressor cells (MDSCs) are a population with immunosuppressive characteristics in the tumor microenvironment, which are linked to poor prognosis and therapeutic resistance across cancers. In this review, a novel concept of MDSCs and a quantity-quality pattern are proposed to illustrate the spatiotemporal dynamics of MDSC fate. By reviewing current researches through this framework, a group of pro-tumor signals is identified to have critical roles in the whole life cycle of MDSC evolution, including immature myeloid cell proliferation, differentiation education, suppressive functioning of MDSCs, and targeting strategy.
MeSH Terms
Humans; Neoplasms; Myeloid-Derived Suppressor Cells; Tumor Microenvironment; Drug Resistance, Neoplasm; Animals; Cell Differentiation; Cell Proliferation
같은 제1저자의 인용 많은 논문 (5)
- A brief review and case report of pheochromocytoma misdiagnosed as allergic vasculitis with bilateral lower extremity ulcers: a 24-year clinical course.
- Symptom Clusters in Children With Leukemia Receiving Chemotherapy: A Scoping Review.
- Ginkgetin inhibits non-small cell lung cancer via the HSP90-AKT signaling pathway.
- Global trends and inequities in childhood cancer burden from 1990 to 2021, with projections to 2040: a Global Burden of Disease study.
- Design, synthesis and biological evaluation of novel glutaminyl cyclase inhibitors targeting the CD47-SIRPα axis in breast cancer cells.